Puma Bio establishes Nerlynx commercialization in Latin America

|About: Puma Biotechnology, Inc. (PBYI)|By:, SA News Editor

Puma Biotechnology (NYSE:PBYI) inks an agreement with Pint Pharma International S.A. granting the latter rights to commercialize NERLYNX (neratinib) in Latin America, including Mexico.

Pint will be responsible for regulatory submissions and all commercialization activities. Puma will receive an upfront payment, up to $34.5M in milestones and double-digit royalties on net sales in the territory.

PBYI is up 2% premarket on light volume.

Subscribe for full text news in your inbox